SHENZHEN, China and BOSTON-XtalPi, a physics-based, AI-powered pharmatech, announced a partnership with MIT Professor of Chemistry Bradley L. Pentelute to advance research in peptide chemistry and molecular biology.

Cambridge, MA and Shenzhen, China – March 7, 2022 – XtalPi, a pioneering artificial intelligence (AI) drug research and development (R&D) company today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry. 

SHENZHEN, China & BOSTON - Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and successfully identified pre-clinical candidates for a new gastric cancer target in approximately six months. The follow-on project will continue to combine XtalPi’s AI drug discovery platform with Signet’s unique novel organoid disease models to generate pipeline candidates and advance them toward clinical trials.

XtalPi, a leading AI drug discovery company, announces a research collaboration with Acerand Therapeutics, a biotechnology company specialized in developing best-in-class and or first-in-class drugs. The partnership will leverage XtalPi's highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.

XtalPi and Sedec have recently reached an agreement to develop novel small-molecule therapeutics targeting STAT3 palmitoylation pathway for auto immune disorder diseases treatment.

CAMBRIDGE, Mass., March 23, 2021 -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable disease targets. The investment round totaled $46 million and was led by BGF, with participation from XtalPi and a panel of new and existing investors. XtalPi Chief Strategy Officer (CSO) Dr. Alan Jiang will join PhoreMost Board of Directors.

XtalPi and Singleron will simultaneously conduct target validation and drug discovery, pursuing multiple promising targets and research paths in parallel.

Led by SoftBank Vision Fund, PICC Capital, and Morningside

XtalPi and PhoreMost sign drug discovery collaboration to discover novel inhibitors of "undruggable" targets

Combining AI Algorithms with Targeted Experiments to Solve Bottleneck Challenges in Drug Development

XtalPi team shares the timeline and preliminary results on their research of the new coronavirus.

XtalPi named as one of World's Top 20 AI Drug Development Companies